Results 251 to 260 of about 54,977 (304)
Daraxonrasib: A Breakthrough in Pancreatic Ductal Adenocarcinoma. [PDF]
CureusZacharia GS +7 more
europepmc +1 more source
Spatially resolved tissue architecture and computational pathology in pancreatic cancer. [PDF]
Exp Mol MedBae SW, Tsirigos A, Min J, Maitra A.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Cancer Discovery, 2021
Abstract Zenocutuzumab, an investigational bispecific antibody, has shown early efficacy in an ongoing phase I/II study of patients with tumors harboring NRG1 fusions. The data so far appear particularly promising in NRG1 fusion–positive pancreatic ductal adenocarcinoma, which tends to occur in younger patients.
openaire +2 more sources
Abstract Zenocutuzumab, an investigational bispecific antibody, has shown early efficacy in an ongoing phase I/II study of patients with tumors harboring NRG1 fusions. The data so far appear particularly promising in NRG1 fusion–positive pancreatic ductal adenocarcinoma, which tends to occur in younger patients.
openaire +2 more sources
A Bacterial-Based Immunotherapy for PDAC
Cancer Discovery, 2022Abstract Researchers have used the bacterium Listeria monocytogenes to deliver tetanus toxoid to mice with pancreatic ductal adenocarcinoma. In these mice, previously vaccinated for tetanus, memory T cells were reactivated to subsequently destroy the tumors. Plans are underway to evaluate this approach in a phase I trial.
openaire +2 more sources
A role for lipid transporters in PDAC
Science Signaling, 2021ApoE mediates immune suppression in pancreatic ductal adenocarcinoma.
openaire +2 more sources
Unlocking PDAC initiation with AP-1
Nature Cancer, 2021Chronic pancreatitis is a risk factor for pancreatic cancer; however, the mechanisms underlying cellular susceptibility to oncogenic transformation are complex. A recent study reports a damage-associated progenitor cell state, controlled by the transcription factors KLF5 and members of the AP-1 family, that initiates tumorigenesis in mouse models of ...
Lindsay M. LaFave, Jason D. Buenrostro
openaire +2 more sources
Broadening Diversity in PDAC Trials
Cancer Discovery, 2021Abstract Findings from a simulated pancreatic cancer trial indicate that some common eligibility criteria, including infectious comorbidities, disproportionately disqualify more Black than white patients from being enrolled. The researchers proposed alternative criteria, showing that the changes could eliminate the imbalance in ...
openaire +2 more sources
Pancreatitis and PDAC: association and differentiation
Abdominal Radiology, 2019The discrimination of mass-forming chronic pancreatitis (MFCP) from pancreatic ductal adenocarcinoma (PDAC) is a central diagnostic dilemma. It is important to differentiate these entities since they have markedly different prognoses and management.
Sherif B. Elsherif +5 more
openaire +2 more sources
2020
Large-scale sequencing analyses have transformed our understanding of PDAC and have defined several molecular taxonomies that now guide pre-clinical and clinical therapeutic development. The identification of molecularly defined subgroups of patients with distinct biological underpinnings and potential therapeutic vulnerabilities promises a step change
Holly Brunton +3 more
openaire +1 more source
Large-scale sequencing analyses have transformed our understanding of PDAC and have defined several molecular taxonomies that now guide pre-clinical and clinical therapeutic development. The identification of molecularly defined subgroups of patients with distinct biological underpinnings and potential therapeutic vulnerabilities promises a step change
Holly Brunton +3 more
openaire +1 more source